IP Library › Granted Patent US 12,448,413
Granted Patent B2
US 12,448,413 · App. 17/693,046 · Granted Oct 21, 2025

HSP70-derived peptide, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen presenting cell

Inventors: Tomoya Miyakawa (Tokyo, JP); Masaaki Oka (Yamaguchi, JP); Shoichi Hazama (Yamaguchi, JP); Koji Tamada (Yamaguchi, JP); Keiko Udaka (Kochi, JP)
Assignee: NEC CORPORATION
C07K7/06A61K38/00A61K40/19A61K40/24A61K40/4262A61K47/50C12N15/09A61K2039/545A61K2239/31A61K2239/38A61K2239/53
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,448,413
App. No.
17/693,046
Granted
Oct 21, 2025
Kind
B2
Abstract

The present invention provides a peptide containing 8 or more consecutive amino acid residues in an amino acid sequence of any of SEQ ID NOS: 1 to 15 and consisting of 11 or less amino acid residues.

Claims (8)

1. A pharmaceutical composition for inducing an immune response in a subject suffering from cancer, comprising a peptide consisting of a variant of the amino acid sequence of SEQ ID NO: 7,

wherein the variant consists of nine amino acid residues, and wherein in the amino acid sequence of the variant, the amino acid corresponding to position 2 of the amino acid sequence of SEQ ID NO: 7 is substituted by tyrosine, phenylalanine, methionine, tryptophan, valine, leucine, or glutamine; and/or the amino acid at the C-terminal is substituted by phenylalanine, leucine, tryptophan, methionine, or valine.

2. The pharmaceutical composition according to claim 1 , wherein the composition is in the form of a vaccine.

3. The pharmaceutical composition according to claim 1 , wherein the peptide can bind to one or more types of HLA molecules.

4. A pharmaceutical composition for inducing an immune response to treat cancer, comprising a peptide consisting of a variant of the amino acid sequence of SEQ ID NO: 7,

wherein the variant consists of nine amino acid residues, and wherein in the amino acid sequence of the variant, the amino acid corresponding to position 2 of the amino acid sequence of SEQ ID NO: 7 is substituted by tyrosine, phenylalanine, methionine, tryptophan, valine, leucine, or glutamine; and/or the amino acid at the C-terminal is substituted by phenylalanine, leucine, tryptophan, methionine, or valine.

5. The pharmaceutical composition according to claim 4 , wherein the composition is in the form of a vaccine.

6. The pharmaceutical composition according to claim 4 , wherein the peptide can bind to one or more types of HLA molecules.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 12, 2023
From: CYTLIMIC INC.
To: NEC CORPORATION
Reel/Frame 062357/0203 →
Priority Claims (1)
JP 2014-206730 · Oct 7, 2014 · national
Continuity (3)
Division 16715758 · Dec 16, 2019
Division 15516918
Related Publication 20220193213A1 · Jun 23, 2022
References Cited (117)
US 5196523A · Lee · 1993 [cited by applicant]
US 7105162B1 · Schmidt et al. · 2006 [cited by applicant]
US 20020192195A1 · Triebel · 2002 [cited by applicant]
US 20030171280A1 · Soderstrom · 2003 [cited by applicant]
US 20040063173A1 · Multhoff · 2004 [cited by applicant]
US 20070081991A1 · Soderstrom · 2007 [cited by applicant]
US 20070087009A1 · Burdin et al. · 2007 [cited by applicant]
US 20090035330A1 · Dewerchin · 2009 [cited by applicant]
US 20090123460A1 · Noelle et al. · 2009 [cited by applicant]
US 20090155308A1 · Moon et al. · 2009 [cited by applicant]
US 20090239806A1 · Nishimura et al. · 2009 [cited by applicant]
US 20100015101A1 · Sato et al. · 2010 [cited by applicant]
US 20100028373A1 · Fujioka et al. · 2010 [cited by applicant]
US 20110028403A1 · Le Poole et al. · 2011 [cited by applicant]
US 20130217122A1 · Kaplan · 2013 [cited by applicant]
US 20140112943A1 · Celis · 2014 [cited by applicant]
US 20150023992A1 · Sette et al. · 2015 [cited by applicant]
US 20150064217A1 · Cornforth et al. · 2015 [cited by applicant]
US 20150285806A1 · Ohtomo et al. · 2015 [cited by applicant]
US 20180071362A1 · Miyakawa et al. · 2018 [cited by applicant]
CA 2963909A1 · 2016 [cited by applicant]
CN 1211926A · 1999 [cited by applicant]
CN 101311270A · 2008 [cited by applicant]
CN 101568550A · 2009 [cited by applicant]
EP 1002108 · 2000 [cited by applicant]
EP 1750707 · 2007 [cited by applicant]
EP 2214705 · 2010 [cited by applicant]
EP 2214705B1 · 2010 [cited by applicant]
EP 2572715A1 · 2013 [cited by applicant]
JP 08151396A · 1996 [cited by applicant]
JP 2001510806A · 2001 [cited by applicant]
JP 2006512391A · 2006 [cited by applicant]
JP 2007514725A · 2007 [cited by applicant]
JP 2008540625A · 2008 [cited by applicant]
JP 2010538655A · 2010 [cited by applicant]
JP 2011506309A · 2011 [cited by applicant]
RU 2333767C2 · 2007 [cited by applicant]
RU 2709015C2 · 2019 [cited by applicant]
WO WO9904810A2 · 1999 [cited by applicant]
WO 0197827A1 · 2001 [cited by applicant]
WO WO2004018667A1 · 2004 [cited by applicant]
WO WO2005060966A1 · 2005 [cited by applicant]
WO WO2007018199A1 · 2007 [cited by applicant]
WO WO2007119515A1 · 2007 [cited by applicant]
WO WO2008106491A2 · 2008 [cited by applicant]
WO WO2009008719A2 · 2009 [cited by applicant]
WO WO2009072767A2 · 2009 [cited by applicant]
WO WO2011044246A1 · 2011 [cited by applicant]
WO WO2013119863A1 · 2013 [cited by applicant]
WO WO2013143026A1 · 2013 [cited by applicant]
WO WO2014097648A1 · 2014 [cited by applicant]
WO WO2014134355A1 · 2014 [cited by applicant]
WO WO2015168379A2 · 2015 [cited by applicant]
WO WO2016056596A1 · 2016 [cited by applicant]
WO WO2016143816A1 · 2016 [cited by applicant]
WO WO2016163489A1 · 2016 [cited by applicant]
Figueiredo et al, Blood 113:No. 13, p. 30089-3016, 2009 (Year: 2009). [cited by examiner]
AdipoGen™ Safety Data Sheet, “LAG-3 (mouse):Fc mMouse) (rec),” May 5, 2011, 3 pages. [cited by applicant]
Allowance dated Apr. 7, 2021 in CN 201680014548.9. [cited by applicant]
American Cancer Society, “Non-specific cancer immunotherapies and adjuvants,” Aug. 8, 2016, 4 pages. [cited by applicant]
Ammi et al., “Poly(I:C) as cancer vaccine adjuvant: Knocking on the door of medical breakthroughs,” Pharmacology & Therapeutics, 2015, vol. 146, pp. 120-131. [cited by applicant]
Belikov, V.G., Vysshaya Shkola, 1993, 43-47. [cited by applicant]
Brignone et al., “A Soluble Form of Lymphocyte Activation Gene-3 (IMP321) Induces Activation of a Large Range of Human Effector Cytotoxic Cells,” The Journal of Immunology, 2007, 179:4202-4211. [cited by applicant]
Ebner et al., “Identification of Multiple T Cell Epitopes on Bet v I, the Major Birch Pollen Allergen, Using Specific T Cell Clones and Overlapping Peptides,” The Journal of Immunology, Feb. 1, 1993, 150(3):1047-1054. [cited by applicant]
Faure et al., “Inducible Hsp70 as Target of Anticancer Immunotherapy: Identification of HLA-A*0201-Restricted Epitopes,” Int. J. Cancer, Mar. 1, 2004, 108(6):863-870. [cited by applicant]
Fougeray et al., “A soluble LAG-3 protein as an immunopotentiator for therapeutic vaccines: Preclinical evaluation of IMP321,” Vaccine, Jun. 29, 2006, 24(26):5426-5433. [cited by applicant]
Fransen et al., “Local immunomodulation for cancer therapy,” OncoImmunology, Nov. 1, 2013, 2(11):e26493, 3 pages. [cited by applicant]
Galluzzi et al., “Trial Watch: Experimental Toll-like receptor agonists for cancer therapy,” OncoImmunology, Aug. 1, 2012, 1(5):699-739. [cited by applicant]
Goldberg et al., “LAG-3 in Cancer Immunotherapy,” Curr. Top. Microbiol. Immunol., Jan. 1, 2011, 344:269-278. [cited by applicant]
Guha, Malini, “Anticancer TLR agonists on the ropes,” Nature Reviews Drug Discovery, Jul. 2012, 11(7):503-505. [cited by applicant]
Harig et al., “Induction of cytotoxic T-cell responses against immunoglobulin V region-derived peptides modified at human leukocyte antigen-A2 binding residues,” Blood, Nov. 15, 2001, 98(10):2999-3005. [cited by applicant]
International Search Report dated Jun. 14, 2016, in PCT/JP2016/057356. [cited by applicant]
International Search Report dated Jun. 27, 2017, in PCT/JP2017/015227. [cited by applicant]
International Search Report dated Jun. 28, 2016, in PCT/JP2016/061463. [cited by applicant]
International Search Report dated Nov. 24, 2015, in PCT/JP2015/078504. [cited by applicant]
Iwama et al., “Identification of an H2-K [cited by applicant]
Jiang et al., “Expression significance of HLA-DR antigen and heat shock protein 70 in hepatocellular carcinoma,” World Chinese Journal of Digestology, Oct. 15, 2001, 9(10):1139-1142, with English abstract. [cited by applicant]
Kano et al., “Combined adjuvants of poly(I:C) plus LAG-3-Ig improve antitumor effects of tumor-specific T cells, preventing their exhaustion,” Cancer Sci., Apr. 15, 2016, 107(4):398-406. [cited by applicant]
Komori et al., “Identification of HLA-A2- or HLA-A24-Restricted CTL Epitopes Possibly Useful for Glypican-3-Specific Immunotherapy of Hepatocellular Carcinoma,” Clin. Cancer Res., May 1, 2006, 12(9):2689-2697. [cited by applicant]
Mashkovsky, M.D., Navaya Volna, 2001, 1(14):11. [cited by applicant]
Multhoff et al., “A 14-mer Hsp70 peptide stimulates natural killer (NK) cell activity,” Cell Stress & Chaperones, Oct. 1, 2001, 6(4):337-344. [cited by applicant]
Nakatsura et al., “Mouse Homologue of a Novel Human Oncofetal Antigen, Glypican-3, Evokes T-Cell-Mediated Tumor Rejection without Autoimmune Reactions in Mice,” Clinical Cancer Research, Dec. 15, 2004, 10(24):8630-8640. [cited by applicant]
O'Beirne et al., “Generation of functional CD8 T Cells by Human dendritic cells expressing glypican-3 epitopes,” Journal of Experimental & Clinical Cancer Research, 2010, 29:48, 11 pages. [cited by applicant]
Office Action dated Aug. 29, 2019, in RU 201735038, with English translation. [cited by applicant]
Office Action dated Jan. 28, 2019, in U.S. Appl. No. 15/556,694. [cited by applicant]
Office Action dated Jun. 17, 2019, in U.S. Appl. No. 15/564,604. [cited by applicant]
Office Action dated Jun. 22, 2021, in CN 201580054234.7, with English translation. [cited by applicant]
Office Action dated Mar. 17, 2020, in AU 2016244570. [cited by applicant]
Office Action dated May 19, 2020, in RU 2019113989, with English translation. [cited by applicant]
Office Action dated May 28, 2020, in CN 201580054234.7, with English translation. [cited by applicant]
Office Action dated Oct. 17, 2017, in JP 2017-511073. [cited by applicant]
Office Action dated Oct. 17, 2019, in TW 104133022. [cited by applicant]
Office Action dated Sep. 1, 2020 in Chinese Application No. 201680014548.9, with English translation. [cited by applicant]
Office Action dated Sep. 20, 2019, in RU 2017134693, with English translation. [cited by applicant]
Office Action issued Mar. 23, 2018, in Russian Application No. RU 2017115719, with English translation. [cited by applicant]
Okochi et al., “Identification of HLA-A24-Restricted Epitopes with High Affinities to Hsp70 Using Peptide Arrays,” Journal of Bioscience and Bioengineering, Mar. 2008, 105(3):198-203. [cited by applicant]
P.H.N. Celie et al., “Crystal structure of MHC CLass | HLA-A2.1 bound to HIV-1 envelope peptide env120-128,” RCSB Protein Data Bank, 2010, https://www.rcsb.org/structure/2X40, 6 pages. [cited by applicant]
Pan et al., “Interferon-y is an autocrine mediator for dendritic cell maturation,” Immunology Letters, May 26, 2004, 94(1-2): 41-151. [cited by applicant]
Partial European Search Report dated Oct. 29, 2021, in EP 21174944.5. [cited by applicant]
Reed et al., “New horizons in adjuvants for vaccine development,” Trends in Immunology, Dec. 6, 2008, 30(1):23-32. [cited by applicant]
Romano et al., “MART-1 peptide vaccination plus IMP321 (LAG-31g fusion protein) in patients receiving autologous PBMCs after lymphodepletion: results of a Phase I trial,” Journal of Translational Medicine, Apr. 12, 2014… [cited by applicant]
Sabbatini et al., “Phase I Trial of Overlapping Long Peptides from a Tumor Self-Antigen and Poly-ICLC Shows Rapid Induction of Integrated Immune Response in Ovarian Cancer Patients,” Clinical Cancer Research, 2012, 18(2… [cited by applicant]
Shang, Wei, Ed., Clinical Bio-Immunotherapy for Tumors, Tianjin Science and Technology Press, Jan. 31, 2006, 284-285, with English translation. [cited by applicant]
Sierro et al., “The CD4-like molecule LAG-3, biology and therapeutic applications,” Expert Opin. On Ther. Targets, Jan. 2011, 15(1):91-101. [cited by applicant]
Sun et al., “Immune activity evaluation of GPC3 peptides recognized by HLA-A11 restricted T lymphocytes in hepatocellular carcinoma patients,” Beijing Medical Journal, Dec. 31, 2014, 36(9):752-755. [cited by applicant]
Supplemental European Search Report dated Jul. 11, 2018, in EP 15849707.3. [cited by applicant]
Supplementary European Search Report dated Nov. 16, 2018, in EP 16776655.9. [cited by applicant]
Supplementary Partial European Search Report dated Apr. 13, 2018, in EP 15849707.3. [cited by applicant]
Tada et al., “Analysis of cytotoxic T lymphocytes from a patient with hepatocellular carcinoma who showed a clinical response to vaccination with a glypican-3-derived peptide,” International Journal of Oncology, Dec. 31… [cited by applicant]
Udaka et al., “An automated prediction of MHC class I-binding peptides based on positional scanning with peptide libraries,” Immunogenetics, Jul. 8, 2000, 51(10):816-828. [cited by applicant]
Vacchelli et al., “Trial Watch: Toll-like receptor agonists for cancer therapy,” Oncolmmunology, Aug. 1, 2013, 2(8):e25238, 14 pages. [cited by applicant]
Wick et al., “Profound CD8+ T cell immunity elicited by sequential daily immunization with exogenous antigen plus the TLR3 agonist poly(I:C),” Vaccine, 2011, 29:984-993. [cited by applicant]
Zhu et al., “Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models,” Journal of Translational Medicine, Feb. 12, 20… [cited by applicant]
Office Action and Search Report dated Nov. 2, 2022 in CN 201780062815.4. [cited by applicant]
Wurz et al., “Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential,” Therapeutic Advances in Medical Oncology, Jan. 31, 2016, 8(1):4-31. [cited by applicant]
Summons to attend oral proceedings pursuant to Rule 115(1) EPC dated Nov. 28, 2024 in Application No. 21 174 994.5. [cited by applicant]
Victor J. Hruby, “Designing Peptide Receptor Agonists and Antagonists” Nature Reviews Drug Discovery, vol. 1, Nov. 2002, pp. 847-858 (12 pages). [cited by applicant]